CADTH, through the pCODR program, systematically monitors the cancer drug pipeline — cancer drugs currently under development. CADTH diligently tracks drugs in the pipeline to:
- identify new cancer drugs and existing cancer drugs proposed for new indications
- gain awareness of emerging trends in oncology treatment
- assist provincial drug programs, cancer agencies, and CADTH with proactive health system planning and program operations.
As part of our commitment to transparency, CADTH shares these aggregate results on our website.
In addition to the above, we have launched the Cancer Drug Information Pipeline for Patient Groups, which is a collaboration between the Canadian Cancer Action Network and CADTH to support patient groups with longer lead times for submissions to the pCODR program. The Pipeline is a centralized source of information that identifies the new oncology drug products or indications that could be submitted to the pCODR program in the near future. Information in the Pipeline is updated each month. Please access the Pipeline by using the link below.